NeoGenomics, Inc. (NEO)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 444 | 484 | 510 | 592 | 661 | 727 | 766 | 804 |
| Operating profit | $m | -66 | -66 | ||||||
| Net profit | $m | 4 | -8 | -144 | -88 | -79 | -108 | -52 | 5 |
| EPS reported | $ | -4.20 | -2.00 | ||||||
| Operating cashflow per share | $ | 0.20 | 0.85 | ||||||
| Capex per share | $ | 1.05 | 1.13 | ||||||
| FCF per share | $ | -0.85 | -0.28 | ||||||
| Free cash flow | $m | -22 | -7 | ||||||
| Net debt | $m | 250 | 229 | ||||||
| Book value equity | $m | 837 | 786 | ||||||
| Book value per share | $ | 32.65 | 30.03 | ||||||
| Number of shares | m | 25.62 | 26.17 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.36 | 0.38 | ||||||
| P/S LTM | x | 0.41 | 0.39 | ||||||
| P/FCF LTM | x | -13.83 | -40.96 | ||||||
| EV/EBITDA LTM | x | -15.87 | 47.65 | ||||||
| EV/Sales LTM | x | 0.84 | 0.93 | ||||||
| Earnings Yield LTM | % | -35.85% | -12.55% | ||||||
| FCF Yield | % | -7.23% | -2.44% | ||||||
| Quality | |||||||||
| ROE | % | -12.91% | -6.31% | ||||||
| ROIC | % | -5.07% | -5.03% | ||||||
| Operating margin | % | -9.09% | -8.63% | ||||||
| Gross margin | % | +38.85% | +42.92% | ||||||
| FCF/Sales | % | -2.99% | -0.96% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +10.11% | +16.01% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.05 | -0.02 | ||||||
| Net Debt/EBITDA | x | -8.08 | 23.50 | ||||||
| EBIT/Net interest | x | -17.61 | -25.64 | ||||||
| Net debt/market cap | % | +1.36% | +92.70% | ||||||
| Net debt/Equity | x | 0.30 | 0.29 | ||||||
| Gross debt/equity | x | 0.56 | 0.57 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free